The FDA launched an enforcement campaign focused on misleading direct-to-consumer (DTC) drug advertising, issuing nearly 100 cease-and-desist letters and thousands of notices to pharmaceutical companies, telehealth platforms and medical spas. Medical spas promoting compounded GLP-1 products are receiving scrutiny for advertising claims that imply FDA approval or equivalence to GLP-1 branded drugs such as Ozempic and Wegovy.

What Med Spas Should Know

• FDA is now scrutinizing even minor violations, including attention-grabbing visuals, fast scene changes, and implied off-label uses.
• AI-powered surveillance tools are being used to monitor digital and social media advertising, including undisclosed influencer promotions.
• Compounded drugs are not FDA-approved, and implying equivalence to approved medications (e.g., “same active ingredient” or “clinically proven”) can trigger enforcement.

The agency is also initiating rulemaking to close the “adequate provision” loophole, which has allowed companies to omit critical safety information in broadcast and digital ads since 1997. These actions are part of a broader initiative to restore transparency and accountability in drug advertising.

Next Steps for Med Spas

• Audit all advertising for compounded products (GLP-1s).
• Avoid vague or exaggerated language that could imply FDA approval or equivalence to branded drugs.
• Include a fair balance of risks and benefits, with contraindications in promotional materials.
• Prepare for additional enforcement from the FDA; reassess your practices for compliance with FDA advertising rules.

Read more about how the FDA is addressing misleading claims at National Law Review >>

Read FDA press announcement >>